This is an update of the previous European Association of Urology testis cancer guidelines published in 2011, which included major changes in the diagnosis and treatment of germ cell tumours.
To summarise latest developments in the treatment of this rare disease.
Recommendations have been agreed within a multidisciplinary working group consisting of urologists, medical oncologists, and radiation oncologists
A semi-structured literature search up to February 2015 was performed to update the recommendations In addition, this document was subjected to double-blind peer review before publication
This publication focuses on the most important changes in treatment recommendations for clinical stage I disease and the updated recommendations for follow-up
Most changes in the recommendations will lead to an overall reduction in treatment burden for patients with germ cell tumours In advanced stages, treatment intensification is clearly defined to further improve overall survival rates
This is an update of a previously published version of the European Association of Urology guidelines for testis cancer, and includes new recommendations for clinical stage I disease and revision of the follow-up recommendations Patients should be fully informed of all the treatment options available to them
European urology 2015 Aug 18 [Epub ahead of print]
Peter Albers, Walter Albrecht, Ferran Algaba, Carsten Bokemeyer, Gabriella Cohn-Cedermark, Karim Fizazi, Alan Horwich, Maria Pilar Laguna, Nicola Nicolai, Jan Oldenburg
Department of Urology, Medical Faculty, Düsseldorf University, Düsseldorf, Germany Electronic address: urologie@uni-duesseldorf de , Department of Urology, Mistelbach, Austria , Department of Pathology, Fundacio Puigvert, Barcelona, Spain , Department of Oncology, Hematology and Bone Marrow Transplantation with section Pneumology, Universitätskliniken Eppendorf, Hamburg, Germany , Department of Oncology-Pathology, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden , Department of Medicine, University of Paris XI, Villejuif, France , Academic Unit of Radiotherapy and Oncology, Royal Marsden NHS Trust and The Institute of Cancer Research, Sutton, UK , Department of Urology, Amsterdam Medical Centre, Amsterdam University, Amsterdam, The Netherlands , Department of Surgery, Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy , Health Sciences, Høgskolen i Buskerud og Vestfold, Kongsberg, Norway